The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

With their promise to transform disease trajectories, cell and gene therapies (CGTs) are bringing new hope to patients with ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...